[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368672-105":59,"doc-detail-368672-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","blood-based-biomarkers-in-soft-tissue-sarcoma-implications-for-immune-checkpoint-inhibitor-therapy","Blood-based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy","","Soft tissue sarcoma (STS) is a rare, heterogeneous cancer with limited benefit from standard chemotherapy in advanced disease, including modest and short-lived response rates and poor overall survival. Immune checkpoint inhibitors (ICI) show promise for selected STS subtypes, but clinical progress depends on biomarkers that can predict response and monitor treatment effects in individual patients. This narrative review synthesizes current trials and evaluates circulating immune-related prognostic candidates, emphasizing the need for reliable blood-based biomarkers to guide personalized ICI therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/blood-based-biomarkers-in-soft-tissue-sarcoma-implications-for-immune-checkpoint-inhibitor-therapy/368672/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/blood-based-biomarkers-in-soft-tissue-sarcoma-implications-for-immune-checkpoint-inhibitor-therapy/368672.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are immune checkpoint inhibitor (ICI) biomarkers important in advanced soft tissue sarcoma?","Question",{"text":112,"@type":113},"ICI therapy effectiveness varies across STS subtypes, and clinicians need biomarkers that can accurately predict response and monitor treatment effects to improve patient selection and outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations in current treatment outcomes motivate this review?",{"text":117,"@type":113},"In advanced STS, chemotherapy has limited efficacy, with low response rates and typically short progression-free survival, while overall survival remains limited for patients with advanced or metastatic disease.",{"name":119,"@type":110,"acceptedAnswer":120},"Which categories of blood-based biomarkers are discussed for ICI prediction in STS?",{"text":121,"@type":113},"The review summarizes circulating immune-related prognostic biomarkers including haematological indices, peripheral blood mononuclear cells, circulating proteins, and circulating DNA, and evaluates their potential as predictive markers for ICI response.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368672,1791299492,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","DOI: 10.1002/ijc.35477  \nREVIE W  \nBlood-based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy  \nBrie-Anne Mannah 1 | John J. Park 1 | Su Yin Lim 1,2   \n1Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia 2Melanoma Institute Australia,  \nThe University of Sydney, Sydney, New South Wales, Australia  \nCorrespondence  \nSu Yin Lim, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.  \nEmail: [esther.lim@mq.edu.au](esther.lim@mq.edu.au)  \nFunding information  \nMacquarie University Clinical Trials Unit Strategic Fund; Tour de Cure; Macquarie Medical School Collaborative Grant Scheme  \nAbstract  \nSoft tissue sarcoma (STS) is a rare and heterogeneous cancer, comprising approximately 1% of all adult cancers and 7%–15% of all childhood cancers. In the advanced stages, chemotherapy remains the standard-of-care, but efficacy is limited, with a response rate of 15%–30%, and responses are often short-lived, with median progression-free survival typically of 6 months. Moreover, patients with advanced or metastatic STS have a median overall survival of only 18–24 months. Immune checkpoint inhibitors (ICI) have revolutionized the treatment of various cancers including melanoma and non-small cell lung cancer (NSCLC) . Emerging evidence from recent clinical trials indicates that certain STS subtypes may beamenable to immunotherapy. A critical challenge, however, is identifying biomarkers that can accurately predict and enable monitoring of ICI responses, to enable better patient selection and to improve outcomes. This narrative review highlights the current research gap in the treatment of STS patients with ICI therapy, particularly the absence of reliable blood-based biomarkers to predict ICI response. In this review, we examine current clinical trials investigating the efficacy of ICI therapy in patients with STS and summarise circulating immune-related prognostic biomarkers in STS, including haematological indices, peripheral blood mononuclear cells, circulating proteins and DNA, and evaluate their potential as predictive biomarkers for ICI therapy. We propose that these immune-associated molecules may serve as predictive biomarkers to differentiate and monitor ICI response, thus presenting opportunities for personalised treatment for patients with STS.  \nAbbreviations: ASPS, alveolar soft part sarcoma; bFGF, basic fibroblast growth factor; CAPP-Seq, cancer personalized profiling by deep sequencing; CI, confidence interval; CR, complete response; CRP, C reactive protein; CTC, circulating tumour cells; ctDNA, circulating tumour DNA; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; DCR, disease control rate; DFS, diseasefree survival; DSS, disease-specific survival; ESR, erythrocyte sedimentation rate; FDA, Food and Drug Administration; GIST, gastrointestinal stromal tumours; ICI, immune checkpoint inhibitors; IL-1ra, interleukin-1 receptor antagonist; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; LAG-3, lymphocyte-activation gene 3; LMR, lymphocyte-to-monocyte ratio; LMS, leiomyosarcoma; M-CSF, macrophage colony-stimulating factor; M-MDSCs, monocytic myeloid-derived suppressor cells; mOS, median overall survival; mPFS, median progression-free survival; MSI, microsatellite instability; NKG2D, natural killer group 2 member D; NLR, neutrophil-to-lymphocyte ratio; NPR, non-progression rate; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PBMC, peripheral blood mononuclear cells; PD, progressive disease; PD-1, programmed cell death protein 1; PDGRFα, platelet-derived growth factor receptor alpha; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PLR, platelet-to-lymphocyte ratio; PR, partial response; SD, stabl","cbCaijD4NF5djs4r","https://ap.wps.com/l/cbCaijD4NF5djs4r","pdf",2296068,12,"English","# Abstract\n# Background\n## Clinical characteristics of soft tissue sarcoma\n## Current standard-of-care\n## Rationale for immune checkpoint inhibitor therapy\n# Biomarkers and research gap\n## Circulating immune-related prognostic biomarkers","[{\"question\":\"Why are immune checkpoint inhibitor (ICI) biomarkers important in advanced soft tissue sarcoma?\",\"answer\":\"ICI therapy effectiveness varies across STS subtypes, and clinicians need biomarkers that can accurately predict response and monitor treatment effects to improve patient selection and outcomes.\"},{\"question\":\"What limitations in current treatment outcomes motivate this review?\",\"answer\":\"In advanced STS, chemotherapy has limited efficacy, with low response rates and typically short progression-free survival, while overall survival remains limited for patients with advanced or metastatic disease.\"},{\"question\":\"Which categories of blood-based biomarkers are discussed for ICI prediction in STS?\",\"answer\":\"The review summarizes circulating immune-related prognostic biomarkers including haematological indices, peripheral blood mononuclear cells, circulating proteins, and circulating DNA, and evaluates their potential as predictive markers for ICI response.\"}]","Blood-based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy | PDF",1790177979,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5d17c27c9db247b95f44df73d589a81.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1670ade481a8326b0da367e4903458cb.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f858fa6946e1df156e1b0a12286ae61e.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65614332b9d4a16cf2cdf213f66bf370.webp",980,1287]